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between Japanese patients and non-Japanese patients. The 
higher exposure in Japanese patients was likely caused 
by the relatively lower weight of Japanese patients versus 
non-Japanese patients. No tumor responses were observed, 
but six patients exhibited stable disease lasting longer than 
4 months.
Conclusions MK-2206 has an acceptable safety profile in 
Japanese patients with advanced solid tumors and warrants 
further investigation.
Keywords MK-2206 · pan-AKT inhibitor · 
Pharmacokinetics · Phase I study · Skin toxicity
Introduction
AKT, also known as a protein kinase B (PKB), is a ser-
ine–threonine kinase that exists in three different isoforms: 
AKT1, AKT2, and AKT3 [1]. AKT is a key regulator of 
the phosphatidylinositol 3-kinase (PI3K)/AKT/mamma-
lian target of rapamycin (mTOR) signaling pathway and is 
important for promoting cell survival and inhibiting apop-
tosis [1]. AKT is frequently activated in many human solid 
tumors as a consequence of overexpression or activating 
mutations of receptor tyrosine kinases, PI3K and Ras, the 
inactivation of tumor suppressor PTEN, and the amplifica-
tion or mutation of AKT itself [1]. Thus, AKT is a crucial 
component of the PI3K/AKT/mTOR signaling pathway 
and is considered an attractive target for the development 
of new anticancer drugs.
MK-2206 is an oral, highly selective inhibitor of AKT 
that binds at a site in the pleckstrin homology (PH) domain, 
distinct from the ATP-binding pocket, resulting in a con-
formational change that prevents the localization of AKT 
to the plasma membrane and its subsequent activation [2]. 
Abstract 
Purpose MK-2206 is an oral, highly selective inhibitor of 
AKT. The safety, tolerability, pharmacokinetics (PK), and 
anti-tumor activity of MK-2206 was evaluated in Japanese 
patients with advanced solid tumors.
Methods Patients received a single oral dose of MK-2206 
according to an every other day (QOD) dosing schedule or 
a once weekly (QW) dosing schedule in repeating 28-day 
treatment cycles, with a 7-day rest after only the first cycle. 
The dose-limiting toxicities (DLTs) were evaluated during 
Cycle 1. Full PK sampling was performed during Cycle 1.
Results Twenty-four patients were treated at 45 mg 
(n = 3) or 60 mg (n = 9) QOD or at 135 mg (n = 3) or 
200 mg (n = 9) QW. One patient experienced a DLT 
at 60 mg QOD, and three patients experienced DLTs at 
200 mg QW. No DLTs were observed at 45 mg QOD or 
at 135 mg QW. The DLTs included mucosal inflamma-
tion, hyponatremia, face edema, erythema multiforme, 
and hyperglycemia. Common adverse events related to 
MK-2206 included rash, an elevated insulin c-peptide level, 
stomatitis, pyrexia, eosinophilia, leukopenia, and hypergly-
cemia. PK differences in MK-2206 exposure were observed 
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MK-2206 inhibited purified recombinant AKT isoforms, 
AKT1, AKT2, and AKT3, with an in vitro 50 % inhibi-
tory concentration [IC50] of 8, 12, and 65 nM, respectively 
[3]. In several cancer cell lines, MK-2206 potently inhib-
ited AKT1 kinase activity (IC50 ≈ 20 nM) and blocked the 
AKT2 and AKT3 activities by two to sixfold less potently 
[4]. In in vivo preclinical models, MK-2206 showed anti-
tumor activity as a single agent and enhanced anti-tumor 
activity in combination with standard chemotherapeutic 
agents or molecular targeted drugs [5].
A first-in-human phase 1 study was conducted to deter-
mine the maximum tolerated dose (MTD) of MK-2206 in 
non-Japanese patients with advanced solid tumors using an 
every other day (QOD) dosing schedule. The MTD for the 
QOD dosing schedule was 60 mg/day, based on safety and 
biomarker data. One of 20 (5.0 %) non-Japanese patients 
at 60 mg QOD experienced a DLT (grade 3 skin rash). 
The dose-limiting toxicities (DLTs) included skin rash and 
stomatitis. The most common drug-related adverse events 
included skin rash, nausea, pruritus, hyperglycemia, and 
diarrhea [6]. In view of the long terminal elimination half-
life values of 60–80 h, a once weekly (QW) dosing sched-
ule has also been pursued [7, 8]. The MTD for the QW 
dosing schedule was established at 200 mg/day. Four of 17 
(23.5 %) non-Japanese patients at 200 mg QW experienced 
DLTs (grade 3 skin rash in three patients; grade 3 derma-
titis acneiform in one patient). Significant AKT pathway 
blockade was observed with both continuous QOD and 
intermittent QW dosing of MK-2206 in serially obtained 
tumor and platelet-rich plasma [8].
In the present study, the safety, tolerability, and PK of 
MK-2206 in Japanese patients with advanced solid tumors 
were investigated using the QOD and QW dosing sched-
ules. The tumor response to MK-2206 was also evaluated 
as an exploratory objective.
Materials and methods
Patient eligibility
This study was conducted based on the Declaration of Hel-
sinki and the Guidelines for the Clinical Evaluation Meth-
ods of Anti-Cancer Drugs in Japan (Japanese Ministry of 
Health, Labour, and Welfare notification, dated 1 Novem-
ber 2005). The study was approved by the institutional 
review board of each study site.
The main eligibility criteria were as follows: histo-
logically (or cytologically) confirmed diagnosis of locally 
advanced or metastatic solid tumors that had failed to 
respond to standard therapy or for which no standard ther-
apy exists; a patient age of 20 years or older; an Eastern 
Cooperative Oncology Group performance status of 0 or 
1; adequate hematologic, hepatic, and renal functions; 
and a hemoglobin A1c (HbA1c) level of 8 % or less. The 
exclusion criteria included the use of chemotherapy, radi-
otherapy, or biological therapy within 4 weeks prior to 
enrollment; primary or unstable central nervous system 
metastasis; and symptomatic ascites or pleural effusion 
requiring treatment. All the patients provided informed 
consent, and the study was conducted in accordance with 
current Good Clinical Practice standards. This study was 
registered at ClinicalTrials.gov as NCT01071018.
Study design and evaluation
This study was an open-label, non-randomized, multi-
center phase 1 study of MK-2206 in Japanese patients with 
locally advanced or metastatic solid tumors. This study was 
designed to investigate the safety and tolerability, PK, and 
anti-tumor activity of MK-2206 when administered accord-
ing to either a QOD or QW dosing schedule.
MK-2206 was administered as an oral formulation at a 
dose of 45 or 60 mg QOD or at a dose of 135 or 200 mg 
QW. Patients took MK-2206 orally at least 2 h before or 
2 h after the intake of food or a meal. Treatment was con-
tinued until disease progression or the occurrence of an 
unacceptable toxicity.
Patients received oral MK-2206 in repeating 28-day 
treatment cycles, with a 1-week rest after only the first 
cycle. The 28 days of Cycle 1 were regarded as the DLT 
evaluation period. A minimum of three and up to nine 
patients were enrolled at each dose level based on the tox-
icity probability intervals [9]. In the DLT assessments, if 0 
of the 3 patients or ≤3 of the 9 patients had a DLT at the 
dose level, the dose level was considered to be tolerable.
Adverse events were graded using the National Can-
cer Institute Common Terminology Criteria for Adverse 
Events, version 3.0. DLT was defined as any of the follow-
ing occurring during Cycle 1 of treatment: grade 4 neu-
tropenia lasting for ≥7 days in duration; grade 3 or 4 neu-
tropenia with a fever >38.5 °C and/or infection requiring 
antibiotic or anti-fungal treatment; grade 4 thrombocyto-
penia; or grade 3 or 4 non-hematologic toxicity, except for 
inadequately treated grade 3 diarrhea, grade 3 nausea and 
vomiting, rash, hyperglycemia, grade 3 elevated transami-
nases of ≤1 week in duration, and inadequately treated 
hypersensitivity reactions; any drug-related adverse event 
leading to a dose modification of MK-2206; unresolved 
drug-related adverse events regardless of grade that lasted 
for 2 weeks or more from the date of the next scheduled 
treatment; persistent increases in the QTc interval (QTc 
>60 ms from baseline and/or >500 ms); and clinically sig-
nificant bradycardia.
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The anti-tumor activity was evaluated at baseline and 
every 6 weeks according to the Response Evaluation Crite-
ria In Solid Tumors (RECIST), version 1.0.
Pharmacokinetics
Blood samples for the QOD dosing schedule were col-
lected for PK analyses just before and 2, 4, 6, 10, 24, and 
48 h after MK-2206 dosing on days 1 and 27 of Cycle 1. 
After the final dose of MK-2206 during Cycle 1, blood 
samples were drawn 96, 144, and 192 h postdose during 
the 1-week rest period. Samples were also drawn directly 
before MK-2206 treatment on days 7, 15, and 21. Blood 
samples for the QW dosing schedule were collected for 
PK analyses just before and 2, 4, 6, 10, 24, 48, and 96 h 
after MK-2206 dosing on days 1 and 22 of Cycle 1. After 
the final dose of MK-2206 in Cycle 1, blood samples were 
drawn 168 and 240 h postdose during the 1-week rest 
period. Samples were also drawn directly before MK-2206 
treatment on days 8 and 15. The blood samples were centri-
fuged, and the plasma was separated and stored at −20 °C. 
The plasma concentrations were analyzed using high-per-
formance liquid chromatography with tandem mass spec-
troscopy (HPLC–MS/MS) at Merck Research Labs, West 
Point, PA. Validation data revealed an adequate accuracy, 




Twenty-four Japanese patients with advanced solid tumors 
were enrolled and were evaluated in this study. Among the 
24 patients who were treated, three patients were in the 
45-mg QOD cohort, nine patients were in the 60-mg QOD 
cohort, three patients were in the 135-mg QW cohort, and 
nine patients were in the 200-mg QW cohort. The baseline 
characteristics of the patients are summarized in Table 1. 
The age range was 38.0–71.0 years (median: 57.0 years), 
and the most frequent solid tumors were colorectal cancer 
(25.0 %) and breast cancer (16.7 %). The median number 
of prior chemotherapy regimens was 3.5 (range 1.0–8.0). 
The median number of treatment cycles (1 cycle: 4 weeks) 
was 4.0 (range 2.0–6.0) for the 45-mg QOD cohort, 2.0 
(range 1.0–12.0) for the 60-mg QOD cohort, 2.0 (range 
2.0–4.0) for the 135-mg QW cohort, and 2.0 (range 1.0–
5.0) for the 200-mg QW cohort. The patients discontinued 
the study treatment because of drug-related adverse events 
(n = 1, grade 2 rash), withdrawal of consent (n = 2), or 
progressive disease (n = 21).
Safety and tolerability
The QOD dosing schedule was investigated in two cohorts 
receiving 45 mg or 60 mg, and the QW schedule was inves-
tigated in two cohorts receiving 135 or 200 mg. The DLTs 
occurring during Cycle 1 (28 days) were evaluated. No 
DLTs were observed in the three patients in the 45-mg 
QOD cohort. One of the nine patients in the 60-mg QOD 
cohort experienced a DLT (grade 3 mucosal inflammation). 
The time until the onset of the DLT after the start of treat-
ment was 28 days. For the QW dosing schedule, no DLTs 
were observed in the 135-mg QW cohort. Three of the nine 
patients in the 200-mg QW cohort experienced DLTs: one 
patient had grade 4 hyponatremia (time until onset, 10 days), 
one patient had grade 3 facial edema and grade 3 erythema 
multiforme (time until onset: 10 days for both DLTs), and 
one patient had grade 3 hyperglycemia and grade 3 erythema 
multiforme (time until onset: 11 days for both DLTs). The 
skin toxicities were manageable with topical, oral, and/or 
intravenous steroid therapy. No treatment-related deaths 
occurred in this study. One patient in the 200-mg QW cohort 
discontinued treatment because of grade 2 rash.
Table 1  Baseline characteristics of the patients (n = 24)
a Ovarian cancer, renal pelvis cancer, renal cancer, mediastinal 

















 Colorectal cancer 6
 Breast cancer 4
 Leiomyosarcoma 3
 Cervical cancer 2
 Esophageal cancer 2
 Gastrointestinal stromal tumor 2
 Othersa 5
No. of prior systemic therapy
 Median 3.5
 Range 1–8
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The common drug-related adverse events reported for 
all the treatment cycles in all the arms are summarized in 
Table 2. The most common hematological adverse events 
related to MK-2206 included eosinophilia (13/24; 54.2 %), 
leukopenia (12/24; 50.0 %), lymphopenia (9/24; 37.5 %), 
and neutropenia (9/24; 37.5 %). The most common 
non-hematological adverse events related to MK-2206 
included rash (20/24; 83.3 %), an elevated insulin c-peptide 
level (16/24; 66.7 %), stomatitis (14/24; 58.3 %), pyrexia 
(13/24; 54.2 %), hyperglycemia (12/24; 50.0 %), diarrhea 
(10/24; 41.7 %), and an elevated blood creatinine level 
(8/24; 33.3 %).
Table 2  Common adverse events related to study medications
All grades of adverse events reported in four or more patients are listed
45 mg QOD (n = 3) 60 mg QOD (n = 9) 135 mg QW (n = 3) 200 mg QW (n = 9) Total (n = 24)
All grades Grades 3–5 All grades Grades 3–5 All grades Grades 3–5 All grades Grades 3–5 All grades Grades 3–5
Blood and lymphatic system disorders
 Eosinophilia 2 0 6 0 1 0 4 0 13 0
 Leukopenia 2 0 2 0 0 0 8 1 12 1
 Lymphopenia 2 2 5 2 0 0 2 2 9 6
 Neutropenia 2 1 2 0 1 0 4 0 9 1
Gastrointestinal disorders
 Stomatitis 2 0 6 0 0 0 6 0 14 0
 Diarrhea 1 1 5 0 1 0 3 0 10 1
 Nausea 0 0 1 0 1 0 3 1 5 1
 Vomiting 0 0 0 0 1 0 3 0 4 0
General disorders and administration site conditions
 Pyrexia 1 0 7 0 0 0 5 0 13 0
 Fatigue 1 0 4 0 1 0 4 0 10 0
 Localized edema 0 0 0 0 0 0 4 0 4 0
Metabolism and nutrition disorders
 Hyperglycemia 1 0 3 0 2 0 6 2 12 2
 Decreased 
appetite
1 0 1 0 1 0 4 1 7 1
 Hypernatremia 0 0 1 0 0 0 4 1 5 1
 Hypoalbumine-
mia
0 0 2 0 0 0 2 0 4 0
 Hypokalemia 0 0 1 0 1 0 2 0 4 0
Skin and subcutaneous tissue disorders
 Rash 3 0 9 1 2 0 6 0 20 1
 Pruritus 1 0 4 0 0 0 5 0 10 0
 Dry skin 2 0 0 0 1 0 2 0 5 0
 Erythema multi-
forme





1 0 1 0 0 0 2 0 4 0
Investigations
 Insulin c-peptide 
increased
2 0 7 0 2 0 5 0 16 0
 Blood creatinine 
increased
1 0 1 0 0 0 6 0 8 0
 Eosinophil count 
increased
0 0 0 0 2 0 5 0 7 0
 HbA1C 
increased
0 0 2 0 1 0 4 0 7 0
 ALT increased 0 0 1 0 0 0 3 1 4 1
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Pharmacokinetic evaluation
The mean serum concentration profiles for MK-2206 
are shown in Fig. 1. Descriptive statistics for the PK 
parameters are given in Table 3. After the QOD dosing 
of MK-2206 (45 or 60 mg) in Japanese patients, the peak 
plasma concentrations were reached at a median Tmax 
of 4–6 h. The harmonic mean terminal t½ was 79.6 and 
71.8 h after QOD dosing in the 45- and 60-mg cohorts, 
respectively. The Cmax values on Day 27 were 214 and 
277 nM, respectively, while the AUC0–48h values were 
8490 and 9690 nM h in the 45- and 60-mg QOD cohorts, 
respectively. MK-2206 had accumulated at ratios of 4.59 
and 3.46 on Day 27 after 45- and 60-mg QOD dosing. 
After the QW dosing of MK-2206 (135 and 200 mg) in 
Japanese patients, the peak plasma concentrations were 
reached at a median Tmax of 4–6 h. The harmonic mean 
terminal t½ was 69.3 and 75.6 h after QW dosing in the 
135- and 200-mg cohorts, respectively. The Cmax values 
on Day 22 were 244 and 571 nM, respectively, while the 
AUC0–48h values were 12,800 and 37,600 nM h in the 
135- and 200-mg QW cohorts, respectively. MK-2206 
had accumulated at ratios of 1.37 and 1.62 on Day 
22 after QW dosing in the 135- and 200-mg cohorts, 
respectively.
Tumor response
As an exploratory objective, the tumor response to 
MK-2206 was evaluated according to the RECIST, version 
1.0. Among the 24 patients who were evaluated, no tumor 
responses were observed. Four patients (two with cervical 
cancer, one with leiomyosarcoma, and one with breast can-
cer) had stable disease (SD) for 4 months or longer, while 
two patients (one with mediastinal tumor and one with 
esophageal cancer) had SD for 6 months or longer.
Discussion
The primary objective of this study was to investigate the 
safety and tolerability of single agent MK-2206 adminis-
tered as a single agent in Japanese patients with advanced 
solid tumors. The safety profile of MK-2206 in Japanese 
patients was consistent with that in non-Japanese patients. 
The major DLTs observed in this study were skin tox-
icities, which were recognized as the most common DLTs 
associated with MK-2206 in a previous study examining 
MK-2206 in non-Japanese patients [6–8]. In this study, one 
of nine patients experienced a DLT (mucosal inflamma-
tion) at a dose of 60 mg QOD, and three of nine patients 
Time (hr), First Dose




























135-mg QW  (n=3)
200-mg QW  (n=9)
Trough Day
4 8 12 16 20
Time (hr), Last Dose
0 48 96 144 192 240
Fig. 1  Mean MK-2206 plasma concentration profiles for Japanese patients receiving multiple oral doses of 45 or 60 mg of MK-2206 every 
other day (QOD) for 4 weeks or 135 or 200 mg of MK-2206 once weekly (QW) for 4 weeks (semi-log scale)
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experienced DLTs (hyponatremia, facial edema, erythema 
multiform, and hyperglycemia) at a dose of 200 mg QW. 
The skin toxicities were manageable with topical, oral, and/
or intravenous steroid therapy, and most of the patients who 
experienced a DLT were able to resume MK-2206 treat-
ment after recovering from the toxicities. Most of the skin 
rashes were maculopapular. Maculopapular rashes have 
been commonly reported in association with PI3K inhibi-
tors such as BKM120, which were generally manageable 
with antihistamines and topical steroid therapy, while papu-
lopustular rashes are more frequently reported in associa-
tion with the EGFR inhibitors cetuximab and erlotinib and 
the MEK inhibitors selumetinib and trametinib [10, 11]. 
The other DLTs, such as hyponatremia, hyperglycemia, and 
facial edema, were manageable with appropriate treatment. 
The common adverse events related to MK-2206 included 
rash, an elevated insulin c-peptide level, stomatitis, pyrexia, 
eosinophilia, leukopenia, and hyperglycemia. These 
adverse events have been previously reported in associa-
tion with MK-2206 in non-Japanese patients with advanced 
solid tumors. Based on the above findings, we concluded 
that the dosing schedules for MK-2206 evaluated in this 
study had an acceptable safety profile in Japanese patients 
with advanced solid tumors.
PK differences were observed after exposure to 
MK-2206 in Japanese patients, compared with non-Japa-
nese patients [8]. Consequently, the PK data were analyzed 
using t tests and nonparametric Wilcoxon–Mann–Whitney 
tests because of potential differences in variance. The AUC, 
Cmax, and Ctrough of the patients in the 200-mg QW cohort 
were significantly higher (P < 0.05) than the correspond-
ing values in non-Japanese patients. While the exposures in 
individual Japanese patients overlapped with the exposures 
observed in non-Japanese patients receiving MK-2206, the 
mean exposure values (Cmax and AUC) were higher (1.4–
1.9-fold) in the 45- and 60-mg QOD and the 200-mg QW 
cohorts and lower (0.7–1.3) in the 135-mg QW cohort. The 
exposure to MK-2206 was found to vary according to body 
weight, and analyses of covariance (ANCOVA) models 
that adjusted for weight suggested that the PK differences 
between Japanese and non-Japanese patients can largely be 
attributed to inter-study weight differences, as the weights 
of the Japanese patients were significantly lower than those 
of the non-Japanese patients receiving 200 mg of MK-2206 
(Fig. 2). The apparent terminal half-life (t½) values were 
similar to those observed in non-Japanese patients (com-
pared to ~60–90 h in non-Japanese patients), suggesting 
no marked differences in the elimination rates between 
Japanese and non-Japanese patients. No differences in Tmax 
were observed.
In this study, no tumor responses were observed, but 
6 of the 24 patients (25 %) with various types of tumors 
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appeared to exhibit preliminary signs of anti-tumor activity. 
Oncogenic PI3K pathway activation was not investigated in 
the patients in this study. To further characterize the anti-
tumor activity of single agent MK-2206, a biomarker anal-
ysis examining the PI3K pathway in a clinical study with 
a large sample size will be necessary. PI3K pathway acti-
vation may be associated with resistance to chemotherapy 
and targeted therapy [12–15]. Considering the limited anti-
tumor activity of MK-2206 monotherapy, a combination 
therapy containing MK-2206 may be more efficacious and 
should be pursued. Recently, early clinical evidence from 
clinical studies of MK-2206 used in combination with tar-
geted therapy or chemotherapy has been reported [16, 17], 
and a clinical study including the combination of MK-2206 
with a MEK inhibitor is presently ongoing in patients with 
advanced non-small-cell lung cancer (NSCLC) [18]. Thus, 
further investigation of the use of MK-2206 in combination 
therapies is also warranted in Japanese patients.
In conclusion, MK-2206 has an acceptable safety profile 
in Japanese patients with advanced solid tumors and war-
rants further investigation. PK differences were observed in 
the exposure of Japanese patients to MK-2206, compared 
with non-Japanese patients. These differences in exposure 
are likely due to inter-study differences in the body weights 
of the patients.
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